The AZT treatment reduces the level of several pro-inflammatory cytokines (IL-17, IL-22, and IL-23) and accumulation of DCs, CD4+T cells, CD8+T cells, and Th17 cells in the skin of mice suffering from imiquimod-induced psoriasis. Here, IL22 is linked to psoriasis.